Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vistra Corp (VST) vs Viatris Inc (VTRS) Price & Performance

Vistra CorpTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Vistra Corp vs Viatris Inc — how do they compare? Vistra Corp trades at $161.48 (market cap $52.41B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Vistra Corp is far larger — about 2.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Vistra Corp for 32 Days and Viatris Inc for 57 Days on average.

VSTVTRS
Market Cap
$52.41B$20.03B
Volume
11,278,07414,109,977
Sector
UtilitiesHealth
52-Week High
$210.85$18.27
52-Week Low
$134.71$9.74
Typical Hold Time
32 Days57 Days
Enterprise Value
$74.34B$32.15B
Dividend Yield
0.59%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vistra Corp

Vistra Corp. (VST) trades at $156.14, down 6.35% over 24 hours amid mixed earnings history, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. Technical indicators show a bullish trend with support at $152 and resistance at $164, while fundamentals highlight strong profitability with an 11.55% net income margin and 75.73% ROE. Recent developments include a $4.2 billion US loan for nuclear power expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.

Outlook remains positive with a consensus price target of $215.23 (38% upside), supported by analyst bullishness (91.3% buy ratings) and institutional interest. Key risks include execution on nuclear projects, debt levels, and volatile earnings. The stock offers exposure to the AI power scarcity theme, but investors should monitor Q3 2026 results on November 6 for confirmation of growth trends.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VST
49% Buy51% Sell
Avg holding period · 32 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Vistra Corp

Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.

Read more on VST →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →